Effect of Inhaled Insulin (AERx iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes.

Trial Profile

Effect of Inhaled Insulin (AERx iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs Insulin (Primary) ; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Oct 2009 Actual initiation date changed from Dec 2006 to Nov 2006 as reported by ClinicalTrials.gov.
    • 31 Jan 2008 Status change from in progress to discontinued, as reported by clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top